New study uncovers mechanisms of bacterial dormancy involving protein aggregation

Researchers revealed a mechanism involving protein aggregation that allows bacteria to enter a dormant state

Leuven, 28 January 2025 – Researchers at the VIB-KU Leuven Center for Microbiology and the VIB-KU Leuven Center for Brain & Disease Research revealed a mechanism involving protein aggregation that allows bacteria to enter a dormant state, a phenomenon that is associated with the persistence of infections and the challenge of antibiotic resistance. Their work appears in Nature Communications.

Sleeping bacteria

As antibiotic resistance continues to escalate globally, understanding how bacteria can evade treatment is more critical than ever. Some bacteria can enter dormant states, during which they are not susceptible to antibiotics. Dormant bacteria, including persister cells and viable but non-culturable cells (VBNCs), survive antibiotic exposure and can later ‘reactivate’, leading to recurrent infections. One of the bacteria that can pull off this trick is Escherichia coli, commonly associated with various infections in humans.

Led by Prof. Jan Michiels (VIB-KU Leuven) and Prof. Liselot Dewachter (UCLouvain), the researchers, alongside colleagues from the Switch lab (VIB-KU Leuven), explored the relationship between protein aggregation and bacterial dormancy.

“We found,” says Prof. Dewachter, “that when we subject bacteria to stress, proteins involved in their energy metabolism start to condensate, meaning that they start to clump together in gel-like droplets. Over time, these droplets solidify, which may protect the bacteria and help them survive. Interestingly, while protein aggregation has previously been associated with neurodegenerative diseases like Alzheimer’s, our findings reveal a surprising positive side to protein aggregation. Our work shows that protein aggregates are not necessarily detrimental, but can actually benefit cells by promoting their survival in stressful environments, such as during antibiotic treatment.”

Different states

The authors show that the two processes – bacterial dormancy and protein condensation – are tightly connected. By aggregating several proteins involved in metabolism, the condensation process effectively shuts down bacterial energy production.

Dr. Celien Bollen, first author of the study, explains, “We found that the timing of protein condensation and dormancy is closely linked across different strains of E. coli. This suggests that the process is conserved, potentially offering a therapeutic target for future treatments.”

Importantly, the scientists found that dormant E. coli cells can recover and regrow by dissolving these protein aggregates. The chaperone protein DnaK can literally pull proteins out of the condensates and reactivate bacterial metabolism.

“There are different states of dormancy,” explains Prof. Jan Michiels. “The bacteria first enter a persister state, where metabolism slows down and energy-related proteins start to form condensates, but they still show some activity, akin to a sleeping state. However, if the stress lasts, the protein droplets solidify and the bacteria transition into the VBNC state. In this state, metabolism drops even further, and it takes the bacteria longer to become active again, resembling more of a coma.”
“By disrupting the processes that lead to dormancy,” Bollen adds, “we may be able to improve the effectiveness of existing antibiotics and reduce the incidence of persistent infections. This is particularly relevant in the context of rising antibiotic resistance, which is a significant threat to public health.”
Celien Bollen and Jan Michiels

Publication

Composition and liquid-to-solid maturation of protein aggregates contribute to bacterial dormancy development and recovery. Bollen et al, Nature Communications, 2025.

Funding

This work was supported by FWO, KU Leuven, and VIB.


Gunnar De Winter

Gunnar De Winter

Science Communications Expert, VIB

 

 

Share

Latest stories

Website preview
Blocking lipid production in healthy lung cells can reduce lung metastasis
Leuven, 17 March 2026 - Scientists from the VIB–KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, have discovered how cancer cells can exploit healthy lung cells to support metastatic tumor growth in the lungs. In two complementary studies published in Nature Cell Biology and Cancer Discovery, they show that tumors use lipids produced by lung cells as signals, and that decreasing the lipid production of lung cells can decrease metastasis. The findings point to new therapeutic strategies that target lung cell lipid production, rather than cancer cells themselves, which may also help refine patient selection for ongoing clinical trials targeting this pathway.
press.vib.be
Website preview
Researchers identify major genetic risk factor for rare form of dementia
Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.
press.vib.be
Website preview
Protealis Announces Regulatory Approval of its First Biological Solution MagNfixTM and Launch of Five New Soybean Varieties
Ghent (Belgium), 11 March 2026 – Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces several milestones that significantly strengthen its position in a fast-growing European soybean market. The company has obtained European regulatory approval from EFCI1 (EU Fertilising Products Regulation (FPR) 2019/1009) for MagNfix™, its first biological solution, which is a proprietary soybean inoculant seed coating that is designed to support higher soybean yield and protein content. In addition, Protealis has secured the registration of five new soybean varieties across four European countries. This includes the introduction of two new maturity group (MG) 000 soybean varieties in Poland, the registration of its first maturity group 0000 ultra-early soybean variety in France, and a new soy variety registration for Belgium. In Germany, Protealis received registration for its second 00 MG soybean variety suited for the regions in southern Germany...
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be